The dual-inhibitory effect of miR-338-5p on the multidrug resistance and cell growth of hepatocellular carcinoma

doi:10.1038/s41392-017-0003-4

CORC > 上海药物研究所 > 中国科学院上海药物研究所 > 药物安全性评价中心

	The dual-inhibitory effect of miR-338-5p on the multidrug resistance and cell growth of hepatocellular carcinoma
	Zhao, Yang 1; Chen, Jing1 ; Wei, Wenxin 2; Qi, Xinming1 ; Li, Chunzhu 1; Ren, Jin1
刊名	Signal transduction and targeted therapy
	2018
卷号	3 页码:3
ISSN号	2059-3635
DOI	10.1038/s41392-017-0003-4
文献子类	Article
英文摘要	Chemotherapeutic treatments against hepatocellular carcinoma (HCC) are necessary for both inoperable patients to improve prospects for survival and surgery patients to improve the outcome after surgical resection. However, multidrug resistance (MDR) is a major obstacle to obtaining desirable results. Currently, increasing the chemotherapy sensitivity of tumor cells or discovering novel tumor inhibitors is an effective therapeutic strategy to solve this issue. In the present study, we uncovered the dual-inhibitory effect of miR-338-5p: on the one hand, it could downregulate ABCB1 expression and sensitize HCC cells to doxorubicin and vinblastine by directly targeting the 3'-untranslated region (3'-UTR) of ABCB1, while, on the other hand, it could suppress the proliferation of HCC cells by directly targeting the 3'-UTR of EGFR and reducing EGFR expression. Since EGFR regulates ABCB1 levels, the indirect action of miR-338-5p in ABCB1 modulation was revealed, in which miR-338-5p inhibits ABCB1 expression by targeting the EGFR/ERK1/2 signaling pathway. These data indicate that the miR-338-5p/EGFR/ABCB1 regulatory loop plays a critical role in HCC, and a negative correlation between miR-338-5p and EGFR or ABCB1 was also detected in HCC clinical samples. In conclusion, these findings reveal a critical role for miR-338-5p in the regulation of MDR and proliferation of HCC, suggesting the potential therapeutic implications of miR-338-5p in HCC treatment.
语种	英语
内容类型	期刊论文
源URL	[http://119.78.100.183/handle/2S10ELR8/266341]
专题	药物安全性评价中心
作者单位	1.1Center for Drug Safety Evaluation and Research, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203 China; 2.3Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, 200438 China
推荐引用方式 GB/T 7714	Zhao, Yang,Chen, Jing,Wei, Wenxin,et al. The dual-inhibitory effect of miR-338-5p on the multidrug resistance and cell growth of hepatocellular carcinoma[J]. Signal transduction and targeted therapy,2018,3:3.
APA	Zhao, Yang,Chen, Jing,Wei, Wenxin,Qi, Xinming,Li, Chunzhu,&Ren, Jin.(2018).The dual-inhibitory effect of miR-338-5p on the multidrug resistance and cell growth of hepatocellular carcinoma.Signal transduction and targeted therapy,3,3.
MLA	Zhao, Yang,et al."The dual-inhibitory effect of miR-338-5p on the multidrug resistance and cell growth of hepatocellular carcinoma".Signal transduction and targeted therapy 3(2018):3.